FCH
TEVA icon

Freestone Capital Holdings’s Teva Pharmaceuticals TEVA Stock Holding History

Freestone Capital Holdings’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-258,421
Closed -$5.57M – 454
2018
Q3 		$5.57M Sell
258,421
-7,293
-3% -$169K 0.04% 94
2018
Q2 		$6.46M Buy
265,714
+23,410
+10% +$477K 0.04% 84
2018
Q1 		$4.14M Buy
242,304
+129,176
+114% +$2.52M 0.24% 111
2017
Q4 		$2.14M Sell
113,128
-32,584
-22% -$490K 0.15% 145
2017
Q3 		$2.56M Buy
145,712
+37,583
+35% +$846K 0.18% 129
2017
Q2 		$3.59M Buy
108,129
+16,899
+19% +$523K 0.28% 98
2017
Q1 		$2.93M Buy
91,230
+48,403
+113% +$1.65M 0.23% 120
2016
Q4 		$1.55M Sell
42,827
-53,945
-56% -$2.15M 0.13% 152
2016
Q3 		$4.45M Buy
96,772
+11,341
+13% +$592K 0.41% 50
2016
Q2 		$4.29M Buy
85,431
+17,624
+26% +$938K 0.42% 49
2016
Q1 		$3.63M Buy
67,807
+14,387
+27% +$844K 0.38% 48
2015
Q4 		$3.51M Buy
53,420
+14,978
+39% +$926K 0.36% 43
2015
Q3 		$2.17M Buy
38,442
+25,201
+190% +$1.63M 0.24% 64
2015
Q2 		$783K Buy
+13,241
New +$817K 0.12% 128
2014
Q2 		– Sell
-6,904
Closed -$365K – 253
2014
Q1 		$365K Sell
6,904
-6,229
-47% -$288K 0.06% 151
2013
Q4 		$527K Buy
13,133
+5,088
+63% +$200K 0.09% 185
2013
Q3 		$304K Sell
8,045
-337
-4% -$13.1K 0.05% 278
2013
Q2 		$329K Buy
+8,382
New +$326K 0.07% 241

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Freestone Capital Holdings's TEVA Position: Q4 2018 in Review

Freestone Capital Holdings sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 258,421 shares — an estimated $5.57M sold.

Freestone Capital Holdings first reported a position in TEVA in Q2 2013 and held it in 18 quarters. The position peaked at $6.46M in Q2 2018. 552 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

  • Freestone Capital Holdings reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Freestone Capital Holdings sold 258,421 Teva Pharmaceuticals shares in Q4 2018, an estimated $5.57M.
  • Freestone Capital Holdings first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • Freestone Capital Holdings's Teva Pharmaceuticals position peaked at $6.46M in Q2 2018.
  • 552 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Freestone Capital Holdings's 13F filing for Q4 2018, filed 12 Feb 2019.